Technology Acquisition Agreement - Additional Information (Detail)	1 Months Ended		9 Months Ended
	May 31, 2014 USD ($)	Jun. 30, 2007 USD ($)	Sep. 30, 2019 USD ($) Milestone
Technology Acquisition Agreement [Line Items]
Payment expensed as in-process research and development		$ 650,000
Mallinckrodt Plc [Member]
Technology Acquisition Agreement [Line Items]
Milestone payments contingent amount			$ 5,000,000
Number of milestone payments | Milestone			1
Mallinckrodt Plc [Member] | Rights and Patents Acquired from Questcor Pharmaceuticals Inc [Member] | Maximum [Member]
Technology Acquisition Agreement [Line Items]
Milestone payments contingent amount			$ 52,000,000
Development Target One [Member] | Rights and Patents Acquired from Questcor Pharmaceuticals Inc [Member]
Technology Acquisition Agreement [Line Items]
Milestone payment	$ 500,000
Development targets description			Upon the initiation of the first patient dosing in the Company's Phase 3 clinical trial for Gimoti.
Development Target Four [Member] | Mallinckrodt Plc [Member] | Patented Technology [Member]
Technology Acquisition Agreement [Line Items]
Development targets description			Depend on Gimoti’s commercial success and will only apply if Gimoti receives regulatory approval. In addition, the Company will be required to pay Mallinckrodt a low single digit royalty on net sales of Gimoti.
Milestone payments contingent amount			$ 47,000,000
Expected expiration of patent right			2032